NLS Pharmaceutics announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7M of its common shares, or common share equivalents in lieu thereof, at a purchase price of 25c per share in a registered direct offering. NLS has also agreed to issue in a private placement unregistered warrants to purchase up to an aggregate of 3.5M common shares at an exercise price of 25c per share. The warrants will become immediately exercisable upon issuance and will expire five years from the date of issuance. H.C. Wainwright is acting as the exclusive placement agent for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
